[Neurotropin suppression of the manifestations of the naloxone-provoked withdrawal syndrome in morphine-dependent rats]. 1991

S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia

Neurotropin was developed by Nippon Zoki Pharmaceutical Co. Ltd. It is produced by inoculating vaccine virus into rabbits and the effective substances are extracted from neuro-immuno inflamed cutaneous tissue. In the present study it was found that intraperitoneally administered neurotropin potently inhibits naloxone-precipitated withdrawal syndrome in morphine-dependent rats. Also we get the experimental evidence that neurotropin increases morphine action but has no positive-reinforcing properties. These data indicate the possibility of testing neurotropin as a medicine for treating opiate-abused patients.

UI MeSH Term Description Entries
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009021 Morphine Dependence Strong dependence, both physiological and emotional, upon morphine. Morphine Abuse,Morphine Addiction,Abuse, Morphine,Addiction, Morphine,Dependence, Morphine
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D002389 Catatonia A neuropsychiatric disorder characterized by one or more of the following essential features: immobility, mutism, negativism (active or passive refusal to follow commands), mannerisms, stereotypies, posturing, grimacing, excitement, echolalia, echopraxia, muscular rigidity, and stupor; sometimes punctuated by sudden violent outbursts, panic, or hallucinations. This condition may be associated with psychiatric illnesses (e.g., SCHIZOPHRENIA; MOOD DISORDERS) or organic disorders (NEUROLEPTIC MALIGNANT SYNDROME; ENCEPHALITIS, etc.). (From DSM-IV, 4th ed, 1994; APA, Thesaurus of Psychological Index Terms, 1994) Catatonia, Malignant,Catatonia, Organic,Lethal Catatonia,Organic Catatonic Disorder,Schizophreniform Catatonia,Catatonia, Lethal,Catatonia, Schizophreniform,Catatonias,Catatonias, Lethal,Catatonias, Malignant,Catatonias, Organic,Catatonias, Schizophreniform,Catatonic Disorder, Organic,Catatonic Disorders, Organic,Lethal Catatonias,Malignant Catatonia,Malignant Catatonias,Organic Catatonia,Organic Catatonias,Organic Catatonic Disorders,Schizophreniform Catatonias
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants

Related Publications

S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
May 1977, Life sciences,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
January 1988, Archives internationales de pharmacodynamie et de therapie,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
January 1986, Pharmacology, biochemistry, and behavior,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
April 1978, Archivos de farmacologia y toxicologia,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
September 2003, Life sciences,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
May 1996, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
April 2015, Behavioural pharmacology,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
July 1974, Arzneimittel-Forschung,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
August 1977, Naunyn-Schmiedeberg's archives of pharmacology,
S K Sudakov, and M A Konstantinopol'skiĭ, and L A Surkova, and I V Tiurina, and J Konishi, and H Yumia
July 1979, Neuropharmacology,
Copied contents to your clipboard!